Elsevier

Clinical Therapeutics

Volume 25, Issue 9, September 2003, Pages 2405-2418
Clinical Therapeutics

Original research
An open-label, prospective, observational study of the incidence of coronary artery disease in patients with hiv infection receiving highly active antiretroviral therapy☆

https://doi.org/10.1016/S0149-2918(03)80283-7Get rights and content

Abstract

Background: The association of highly active antiretroviral therapy (HAART) regimens that include protease inhibitors (PIs) with metabolic and somatic disorders has raised concerns about the possibility of an increased risk of coronary artery disease (CAD) in patients with HIV infection.

Objective: The aim of this study was to assess the incidence of CAD in previously untreated HIV infected outpatients who received reverse transcriptase inhibitors with or without PIs.

Methods: In this open-label, multicenter, prospective, observational trial, previously untreated and asymptomatic HIV-infected Italian patients were followed to assess the incidence of CAD (primary end point) according to the HAART regimen they received: 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) in combination with PIs (group PI+) or 1 non-nucleoside reverse transcriptase inhibitor in combination with 2 NRTIs (group PI-). Patients underwent clinical examination and laboratory testing every 4 months.

Results: A total of 1551 HIV-infected patients (994 [64%] men; median age, 35 years; range, 22–50 years) were followed for a median 36 months (range, 34–42 months). The cumulative annual incidence of CAD-related events was 9.8/1000 in group PI+ and 0.8/1000 in group PI- (P < 0.001). The annual incidence of myocardial infarction was 5.1/1000 in group PI+ and 0.4/1000 in group PI- (P < 0.001). Independent of patient age, the incidence of CAD was greater among men (P < 0.001) and patients who smoked >20 cigarettes per day (P < 0.001). Lipodystrophy and metabolic alterations were observed in 62% of patients in group PI+ and in 4% of patients in group PI- (P < 0.001). Of 23 patients receiving PIs who developed CAD, 17 (73.9%) had lipodystrophy and all 23 had hypertriglyceridemia and hypercholesterolemia.

Conclusions: According to our findings, HAART that includes PIs may accelerate the onset of CAD-related events in young, male, heavy smokers who develop metabolic disorders and lipodystrophy during therapy. Patients with increased coronary risk should receive careful cardiac monitoring if treated with PIs.

References (19)

  • S.D. Holmberg et al.

    for the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV 1

    Lancet

    (2002)
  • G. Barbaro

    Cardiovascular manifestations of HIV infection

    Circulation

    (2002)
  • S.A. Bozzette et al.

    Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

    N Engl J Med.

    (2003)
  • N. Friis-Moller et al.

    for the DAD Study Group. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study

    AIDS

    (2003)
  • E. Braunwald

    Unstable angina. A classification

    Circulation

    (1989)
  • A. Carr

    HIV protease inhibitor-related lipodystrophy syndrome

    Clin Infect Dis.

    (2000)
  • M.E. Bertrand et al.

    Circulatory variables measured by invasive techniques. Definitions, abbreviations, units, methods of measurement and normal values. A report of the WHO/ISFC Task Force on Haemodynamics

    Eur Heart J.

    (1985)
  • S. Tsiodras et al.

    Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study

    Arch Intern Med.

    (2000)
There are more references available in the full text version of this article.

Cited by (0)

☆

Portions of this work were presented at the 2002 American Heart Association Scientific Sessions, November 17–20, 2002, Chicago, Illinois, and published as an abstract (Circulation. 2002;106[Suppl 2]:I1-414).

View full text
Copyright © 2003 Published by Elsevier Inc.